gabapentin
Adjunctive therapy • Brands: NEURONTIN
Last reviewed: 2026-02-12
General information
- Primary label indications include: Adjunctive therapy in partial seizures (epilepsy); postherpetic neuralgia (label).
- Class: Adjunctive therapy
- Common US brands: NEURONTIN
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2026-02-12
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Alpha-2-delta (α2δ) ligand that modulates voltage-gated calcium channels and reduces excitatory neurotransmitter release.
Metabolism & Half‑life
- Metabolism: Not appreciably metabolized (label).
- Half‑life: Single-dose range 5–7 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Gabapentin prescribing information (Neurontin) — DailyMed (2026)
- Gabapentin and Pregabalin for the Treatment of Anxiety Disorders — Clinical Pharmacology in Drug Development (2018)
- Treatment of Social Phobia With Gabapentin — Journal of Clinical Psychopharmacology (1999)
- Gabapentin misuse, abuse and diversion: a systematic review — Addiction (2016)
- Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update — Drugs (2021)